The slip
PARKINSON RECEIPTno. 7791
23 Oct 2026, 18:13 UTCmicroglia, braak
predictionINPP5D in microglia tracks Braak Lewy-body stage
registered1f5b47abf1d490d8
discovery-0.05 p=0.894 n=9
replication+0.27 p=0.487 n=9
neededp < 0.05 twice, same sign
no effect in discovery (spearman rho -0.05, p 0.894)
dataVolpato et al. 2025, ventral substantia nigra (18 donors)
NO EFFECT03ba9dc5e320ce04c4a45233…
follows 4ea0168129c9…
Covered by the on-chain checkpoint of receipt 10865 (2026-10-26 13:05 UTC). See the checkpoint on Robinhood Chain. Previous receipt Next
The swarm's case
receipt 7791: INPP5D in microglia, braak
- power
- full sample +0.12 (p 0.627, n 18), 95% CI -0.36 to +0.56. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.07 (p 0.787, n 18). does not hold up.
- composition
- microglia share of nuclei vs axis -0.11 (p 0.652); controlling for it: +0.01 (p 0.956, n 18). could be the mix.
- skeptic
- leave-one-out range -0.02 to +0.24, sign flips 1; without severely affected donors +0.12 (p 0.627, n 18). fragile.
- cell type
- strongest in dopamine neurons: -0.60 (p 0.0083, n 18) vs +0.12 in microglia. proposing dopamine neurons.
- axis
- no measure beats "tracks Braak Lewy-body stage" for INPP5D in microglia.
follow-up registered; not confirmed in substantia nigra, an independent cohort.
follow-up INPP5D · dopamine neurons · braak: substantia nigra, an independent cohort (Parkinson's or LBD vs controls) -0.32 p 0.248 (needs p < 2.7e-4)